316 Participants Needed

Combination Therapy for Breast Cancer

Recruiting at 31 trial locations
RS
RS
Overseen ByReference Study ID Number: CO42867 https://forpatients.roche.com/
Age: 18+
Sex: Female
Trial Phase: Phase 1 & 2
Sponsor: Hoffmann-La Roche
Must be taking: Endocrine therapy
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This trial is testing new treatments for advanced breast cancer in patients whose cancer has not responded to previous treatments. It aims to find more effective drug combinations for these patients. One of the treatments being tested is Lapatinib, which is being evaluated both for patients whose cancer has returned and as an initial treatment option in combination with chemotherapy.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications before starting, such as strong CYP3A4 inhibitors or inducers, and any systemic treatment for breast cancer within 2 weeks of starting the trial. If you are on these medications, you may need to stop them before participating.

What data supports the effectiveness of the drug combination therapy for breast cancer?

Research shows that adding abemaciclib, a CDK4/6 inhibitor, to endocrine therapy significantly improves progression-free survival and response rates in certain types of breast cancer, making it a valuable treatment option. This combination is particularly effective for patients with hormone receptor positive (HR+) and HER2-negative breast cancer, both in early and advanced stages.12345

Is the combination therapy for breast cancer safe for humans?

Abemaciclib, when used with endocrine therapy for certain types of breast cancer, has been found to have a tolerable safety profile, with common side effects including diarrhea, infections, and neutropenia (low white blood cell count). These side effects are generally manageable.24567

What makes the combination therapy for breast cancer unique?

This combination therapy is unique because it includes multiple drugs like Abemaciclib, which is a CDK4/6 inhibitor that helps prevent cancer cells from growing, and other targeted therapies like Trastuzumab-deruxtecan, which specifically targets cancer cells with certain proteins. This multi-drug approach aims to improve effectiveness by attacking the cancer in different ways.12458

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Eligibility Criteria

This trial is for postmenopausal women with advanced or metastatic ER-positive, HER2-negative breast cancer that worsened after CDK4/6 inhibitor treatment. It's also for those with ER-positive, HER2-positive breast cancer resistant to anti-HER2 therapies and trastuzumab-and-taxane-based therapy. Participants must have a life expectancy of at least 3 months and be able to provide a tumor sample.

Inclusion Criteria

My blood and organs are functioning well.
My cancer worsened after hormone therapy including a CDK4/6 inhibitor.
My blood thinner medication dose has been stable.
See 14 more

Exclusion Criteria

I have had major surgery on my stomach or small bowel, or I have a chronic condition causing frequent severe diarrhea.
I have not received a live-virus vaccine in the last 28 days.
I haven't had major heart issues or strokes in the last 3 months.
See 54 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive various treatment combinations based on their cohort, including Giredestrant with other agents like Abemaciclib, Atezolizumab, and others

12-24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term as new treatment arms become available

Long-term

Treatment Details

Interventions

  • Abemaciclib
  • Ado-trastuzumab emtansine
  • Lapatinib
  • Neratinib
  • Palbociclib
  • Pyrotinib
  • Ribociclib
  • Trastuzumab-deruxtecan
  • Tucatinib
Trial Overview The study tests various drug combinations (like Atezolizumab, Palbociclib) in two cohorts based on the type of breast cancer. Patients are randomly assigned to different treatments which may change if they experience disease progression or unacceptable side effects during the initial stage.
Participant Groups
15Treatment groups
Experimental Treatment
Active Control
Group I: Cohort 3: Giredestrant + Inavolisib + RibociclibExperimental Treatment3 Interventions
Group II: Cohort 3: Giredestrant + Inavolisib + PalbociclibExperimental Treatment3 Interventions
Group III: Cohort 3: Giredestrant + Inavolisib + AbemaciclibExperimental Treatment3 Interventions
Group IV: Cohort 2: Giredestrant + PH FDC SC + PalbociclibExperimental Treatment3 Interventions
Group V: Cohort 2: Giredestrant + PH FDC SC + AbemaciclibExperimental Treatment3 Interventions
Group VI: Cohort 1: Giredestrant + SamuraciclibExperimental Treatment2 Interventions
Group VII: Cohort 1: Giredestrant + RibociclibExperimental Treatment2 Interventions
Group VIII: Cohort 1: Giredestrant + IpatasertibExperimental Treatment2 Interventions
Group IX: Cohort 1: Giredestrant + InavolisibExperimental Treatment2 Interventions
Group X: Cohort 1: Giredestrant + EverolimusExperimental Treatment2 Interventions
Group XI: Cohort 1: Giredestrant + AtezolizumabExperimental Treatment2 Interventions
Group XII: Cohort 1: Giredestrant + Abemaciclib + AtezolizumabExperimental Treatment3 Interventions
Group XIII: Cohort 1: Giredestrant + AbemaciclibExperimental Treatment2 Interventions
Group XIV: Cohort 2: Giredestrant + PH FDC SCActive Control2 Interventions
Group XV: Cohort 1: Giredestrant MonotherapyActive Control1 Intervention

Abemaciclib is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Verzenio for:
  • Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
  • HR+, HER2- node-positive early breast cancer
🇪🇺
Approved in European Union as Verzenio for:
  • HR+, HER2- advanced or metastatic breast cancer
  • HR+, HER2- node-positive early breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Findings from Research

The addition of CDK4 and 6 inhibitors (like abemaciclib, palbociclib, or ribociclib) to endocrine therapy significantly improves progression-free survival and response rates in patients with HR+ and HER2- metastatic breast cancer, establishing these inhibitors as a new standard of care.
Exploratory analyses suggest that abemaciclib may be particularly beneficial for women with poor prognosis indicators, although further confirmation is needed for these findings.
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.Martin, M., Garcia-Saenz, JA., Manso, L., et al.[2021]
Interim results from the MONARCH3 study show that abemaciclib, a CDK4/6 inhibitor, is an effective first-line treatment for advanced ER-positive, HER2-negative breast cancer.
Patients receiving abemaciclib in combination with letrozole experienced significantly improved progression-free survival compared to those receiving a placebo with endocrine therapy.
First-Line Abemaciclib Effective in ER+ Breast Cancer.[2019]
A new ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed to effectively monitor abemaciclib levels in patients with advanced breast cancer, showing high accuracy and precision in quantification.
This method allows for robust therapeutic drug monitoring (TDM) of abemaciclib, which can help personalize treatment and improve adherence in patients, addressing challenges in the emerging field of oral antitumor therapies.
An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum.Habler, K., Vogeser, M., Teupser, D.[2022]

References

Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. [2021]
First-Line Abemaciclib Effective in ER+ Breast Cancer. [2019]
An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum. [2022]
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy. [2023]
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence. [2023]
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. [2023]
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. [2022]
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. [2022]